Kopran Limited (KOPRAN.NS)
- Previous Close
193.53 - Open
193.53 - Bid 192.02 x --
- Ask 192.40 x --
- Day's Range
190.99 - 196.28 - 52 Week Range
155.00 - 369.70 - Volume
112,999 - Avg. Volume
281,655 - Market Cap (intraday)
9.301B - Beta (5Y Monthly) 0.56
- PE Ratio (TTM)
24.07 - EPS (TTM)
7.99 - Earnings Date Aug 6, 2025 - Aug 11, 2025
- Forward Dividend & Yield 3.00 (1.55%)
- Ex-Dividend Date Sep 2, 2024
- 1y Target Est
--
Kopran Limited, an integrated pharmaceutical company, engages in the manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti-helmentics, anti-acne, anti-infective, anti-thrombotic, antidiabetic, pain management, neuromodular, gastroenterology, and cardiovascular. In addition, the company provides drugs for erectile dysfunction, antiallergics, respiratory, oncology, central nervous system, antiprotozoal, anthelmintics, antipeptic ulcer and gut, and others. Kopran Limited was incorporated in 1958 and is based in Mumbai, India.
www.kopran.com--
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Recent News: KOPRAN.NS
View MorePerformance Overview: KOPRAN.NS
Trailing total returns as of 6/6/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KOPRAN.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KOPRAN.NS
View MoreValuation Measures
Market Cap
9.36B
Enterprise Value
10.58B
Trailing P/E
24.22
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.48
Price/Book (mrq)
1.80
Enterprise Value/Revenue
1.68
Enterprise Value/EBITDA
13.76
Financial Highlights
Profitability and Income Statement
Profit Margin
6.12%
Return on Assets (ttm)
4.51%
Return on Equity (ttm)
7.64%
Revenue (ttm)
6.3B
Net Income Avi to Common (ttm)
385.52M
Diluted EPS (ttm)
7.99
Balance Sheet and Cash Flow
Total Cash (mrq)
258.64M
Total Debt/Equity (mrq)
28.51%
Levered Free Cash Flow (ttm)
-300.05M